The evolving role of PET-CT in the management of esophageal cancer

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 53, Issue 2, 2009, Pages 201-209

  Chuang, H H ^a   Macapinlac, H A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Esophageal cancer; FDG; PET CT; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; ESOPHAGUS CANCER; HUMAN; METASTASIS; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; REVIEW; TREATMENT RESPONSE; ESOPHAGUS TUMOR; METHODOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ESOPHAGEAL NEOPLASMS; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 69449091876     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. SEER Stat Fact Sheets. Esophagus [Internet]. Bethesda, MD: National Cancer Institute; 2008 [cited 2009 Jan 30]. Available from: http://seer.cancer. gov/statfacts/html/esoph.html
3. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al., MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
4. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-34.
5. Zuccaro G Jr, Rice TW, Goldblum J, Medendorp SV, Becker M, Pimentel R et al. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am J Gastroenterol 1999;94:906-12.
6. Beseth BD, Bedford R, Isacoff WH, Holmes EC, Cameron RB. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg 2000;66:827-31. (Pubitemid 30666925)
7. Pfau PR, Kochman ML. Pretreatment staging by endoscopic ultrasonography does not predict complete response to neoadjuvant chemoradiation in patients with esophageal carcinoma. Gastrointest Endosc 2000;52:583-6.
8. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52.
9. Greene FL, Page DL, Fleming ID, Morrow M. American Joint Commission on Cancer. Esophagus. In: AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002. p. 301-46.
10. Christie NA, Rice TW, DeCamp MM, et al. M1a/M1b esophageal carcinoma: clinical relevance. J Thorac Cardiovasc Surg 1999;118(5):900-7.
11. Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD, Larson SM. FDG-PET in esophageal cancer. Incremental value over computed tomography. Clin Positron Imaging 1999;2:255-60.
12. Lowe VJ, Booya F, Fletcher JG, Nathan M, Jensen E, Mullan B et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol 2005;7:422-30.
13. Bruzzi JF, Truong MT, Macapinlac H, Munden RF, Erasmus JJ. Integrated CT-PET imaging of esophageal cancer: unexpected and unusual distribution of distant organ metastases. Curr Probl Diagn Radiol 2007;36:21-9.
14. van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 2008;98:547-57.
15. Weber WA, Ott K. Imaging of esophageal and gastric cancer. Semin Oncol 2004;31:530-41.
16. Meyers BF, Downey RJ, Decker PA, Keenan RJ, Siegel BA, Cerfolio RJ et al.; American College of Surgeons Oncology Group Z0060. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 2007;133:738-45.
17. Chatterton BE, Ho Shon I, Baldey A, Lenzo N, Patrikeos A, Kelley B et al. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging 2009;36:354-61.
18. Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005;46:752-7. (Pubitemid 43750749)
19. Osman MM, Cohade C, Fishman EK, Wahl RL. Clinically significant incidental findings on the unenhanced CT portion of PET/CT studies: frequency in 250 patients. J Nucl Med 2005;46:1352-5. (Pubitemid 43733487)
20. Salahudeen HM, Balan A, Naik K, Mirsadraee S, Scarsbrook AF. Impact of the introduction of integrated PET-CT into the preoperative staging pathway of patients with potentially operable oesophageal carcinoma. Clin Radiol 2008;63:765-73.
21. van Westreenen HL, Westerterp M, Jager PL, van Dullemen HM, Sloof GW, Comans EF et al. Synchronous primary neoplasms detected on 18F-FDG PET in staging of patients with esophageal cancer. J Nucl Med 2005;46:1321-5.
22. Ott K, Weber W, Siewert JR. The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus 2006;19:433-42.
23. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004;78:1152-60; discussion 1152-60.
24. Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA et al. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol 2006;1:478-86.
25. Iyer RB, Balachandran A, Bruzzi JF, Johnson V, Macapinlac HA, Munden RF. PET/CT and hepatic radiation injury in esophageal cancer patients. Cancer Imaging 2007;7:189-94,
26. Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA et al. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 2007;109:125-34.
27. Jones DR, Parker LA, Jr., Detterbeck FC, Egan TM. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 1999;85:1026-32.
28. Lightdale CJ, Kulkarni KG. Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol 2005;23:4483-9.
29. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 2005;129:1232-41.
30. Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy - systematic review. Radiology 2005;236:841-51.
31. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-65. (Pubitemid 32565444)
32. Wieder HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-8.
33. Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21:428-32.
34. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004;101:1776-85.
35. Brücher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300-9.
36. Nakamura R, Obara T, Katsuragawa S, Tamakawa Y, Koeda K, Ikeda K et al. Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy. Radiat Med 2002;20:181-6.
37. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005;103:1347-55.
38. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 2005;104:1349-55.
39. Gillham CM, Lucey JA, Keogan M, Duffy GJ, Malik V, Raouf AA et al. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 2006;95:1174-9.
40. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002;225:575-81. (Pubitemid 35239264)
41. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200-9. (Pubitemid 39655178)
42. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-7.
43. Allen-Auerbach M, Quon A, Weber WA, Obrzut S, Crawford T, Silverman DH et al. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 2004;6:411-6.
44. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology 2007;242:360-85.
45. Bar-Shalom R, Guralnik L, Tsalic M, Leiderman M, Frenkel A, Gaitini D et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging 2005;32:918-24.
46. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508.
47. Cheze-Le Rest C, Metges JP, Teyton P, Jestin-Le Tallec V, Lozac'h P, Volant A et al. Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study. Nucl Med Commun 2008;29:628-35.
48. Javeri H, Xiao L, Rohren E, Komaki R, Hofstetter W, Lee JH et al. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer 2009;115:624-30.
49. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797-805.
50. Choi JY, Jang HJ, Shim YM, Kim K, Lee KS, Lee KH et al. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med 2004;45:1843-50.
51. Mamede M, Abreu ELP, Oliva MR, Nose V, Mamon H, Gerbaudo VH. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol 2007;30:377-88.
52. van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, Elsinga PH et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med 2005;46:400-4.